Plasma fractionation market forecasts to 2019

The global plasma fractionation market is witnessing continuous growth. The rise in aging population worldwide is an important factor for this market, mainly because the risk of complications of hemophilia, such as inhibitor development, intracranial hemorrhage, and joint diseases, increases along with the age of a person.

Therefore, according to a new report added to the offering of MarketandMarkets, the rise in the aging population can add to the number of hemophilic patients worldwide, which drives the demand for plasma fractionation products such as factor VIII and factor IX, which are used to treat hemophilia.

In addition, the increasing off-label use of albumin and immunoglobulin in various chronic diseases, increased diagnosis rates and a rise in the use of prophylactic treatment for bleeding and immune diseases are expected to propel the growth of this market. However, the high cost of plasma products, serious adverse effects associated with plasma products, and emergence of recombinant products (which can be used as alternative to plasma-derived products) are hampering the growth of the global market to a certain extent.